Healthcare - Biotechnology - NASDAQ - US
$ 4.31
-8.69 %
$ 304 M
Market Cap
-2.52
P/E
INCOME STATEMENT
20.8 M
REVENUE
-139 M
OPERATING INCOME
-132 M
NET INCOME
EFFICIENCY
Earnings Waterfall
C4 Therapeutics, Inc.
| Revenue | 20.8 M |
| Cost Of Revenue | 118 M |
| Gross Profit | -97 M |
| Operating Expenses | 160 M |
| Operating Income | -139 M |
| Other Expenses | -6.54 M |
| Net Income | -132 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Revenue | 20.8 | 31.1 | 45.8 | 33.2 | 21.4 | 19.4 |
| GROSS PROFIT | ||||||
| Cost Of Revenue | 117.7 | 7.6 | 2.9 | 77.5 | 47.7 | 28.6 |
| Gross Profit | (97.0) | 23.5 | 42.9 | (44.3) | (26.3) | (9.2) |
| OPERATING INCOME | ||||||
| Operating Expenses | 159.8 | 160.6 | 127.9 | 93.6 | 56.8 | 35.8 |
| Selling, General and Administrative Expenses | 42.1 | 42.8 | 33.3 | 15.2 | 8.8 | 7.2 |
| Research and Development Expenses | 117.7 | 117.8 | 94.7 | 78.4 | 48.1 | 28.6 |
| Operating Income | (139.0) | (129.5) | (82.1) | (60.4) | (35.5) | (16.4) |
| PRE-TAX INCOME | ||||||
| Interest Income Expense | 1.4 | 2.2 | 2.1 | 1.2 | 0 | 0 |
| Total Other Income | 7.8 | 1.4 | (1.8) | (6.5) | 2.2 | 0.7 |
| Pre-Tax Income | (131.2) | (128.2) | (83.9) | (67.0) | (33.3) | (15.7) |
| NET INCOME | ||||||
| Tax Provision | 1.3 | (1.7) | 2.1 | (0.6) | 0.8 | 0.7 |
| Net Income | (132.5) | (126.5) | (86.0) | (66.3) | (34.1) | (15.7) |
| EPS | 2.67 | 2.59 | 1.87 | 1.54 | 0.79 | 1.06 |